ROAD TO THE CURE UPDATE AUGUST 2015

About 98% of all drugs cannot reach the brain…Some drugs that do reach the brain only “treat symptoms” for a short while.

You need not be a scientist or a physician to learn and understand that drugs have to reach the brain in order for them to be effective in curing brain diseases. Did you know that? Most drugs capable of halting or curing Parkinson’s disease and Alzheimer’s disease do not reach the brain. About 98% of all drugs cannot reach the brain. That is why there are no cures and even diagnostic tests for these horrible diseases. The reason why most drugs cannot reach the brain is that our brain is protected by a physical barrier known as the blood-brain barrier (BBB). This barrier allows essential nutrients to enter the brain while blocking viruses, bacteria, parasites and most drugs from entering the brain. Some drugs that do reach the brain only “treat symptoms” for a short while without altering the course of the disease.

ICBI is one of the very few companies in the world that has been successful in transporting Parkinson’s and Alzheimer’s disease altering drugs to the brain. Its technology, for the first time in the history of mankind, provides a real hope for halting and curing most debilitating neurodegenerative Alzheimer’s and Parkinson’s diseases. This is your real-time report for this month as ICBI’s historic, game-changing work goes forth. Through these updates you are / may be learning so much about how science works. It may be helpful if you also look into how Foundations work. Just because they raise lots of money for research does not mean they dole it out that way. Foundations are typically very cautious, skeptical, and perhaps even biased as to how and who they will grant their funds to.  They may also want control of how and where their name is used; therefore, being respectful of their terms, and conditions we respectfully withhold their names for the time being and submit to you the following:

Grant Award from an Internationally Known Parkinson’s Foundation

ICBI just received the first payment of its grant award from a major internationally known Parkinson’s foundation to further its work for the development of a diagnostic ligand and therapeutic drug for Parkinson’s disease. We have developed a potentially clinically useful diagnostic ligand and a drug, referred to as alpha-synuclein-SMART Molecule (α-Syn-SM), which has been shown in mice to specifically seek and bind to the pathological lesions due to aggregated alpha-synuclein in the brain of Parkinson’s like mice. The new grant award is given to assess the binding of ICBI’s drug to the brain tissues of Parkinson’s patients. This work will be done in collaboration with Dr. Eliezer Masliah of the University of California San Diego.

Invitation to Submit another Grant

ICBI was invited to submit a grant by another well-known foundation in bay area in the amount of $350,000. The terms of the grant are being reviewed by an attorney. If the terms are acceptable, ICBI might submit another grant in the next few weeks. More than the funds, which the Company needs for research and development, the invitation to submit a grant signifies appreciation of what ICBI is developing.

Unsolicited Visit by Representatives of Ono Pharmaceuticals

ICBI was visited by three representatives of Japanese company Ono Pharmaceuticals in the second week of July. ICBI is very thankful to the executives of Ono Pharma who took an initiative to visit its La Jolla facility and talk to its scientists to understand the Company’s technology. These small gestures signify that the scientific community and big pharma is keeping an eye on ICBI’s technology and their progress. Imagine the impact of ICBI technology on the world pharmaceutical industry after it has conducted Phase-1 human clinical trials for which the Company is trying to raise about $3.5M to $5M.